BeOne Medicines Ltd. (HKG:6160)

Market Cap	262.49B
Revenue (ttm)	35.81B
Net Income (ttm)	-1.39B
Shares Out	n/a
EPS (ttm)	-13.05
PE Ratio	n/a
Forward PE	103.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,070,894
Average Volume	5,782,904
Open	179.20
Previous Close	177.20
Day's Range	177.30 - 188.30
52-Week Range	103.10 - 196.90
Beta	0.27
RSI	53.79
Earnings Date	Aug 6, 2025

About BeOne Medicines

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6160

Financial Performance

In 2024, BeOne Medicines's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD